Tscan Therapeutics is trading at $0.23, up 12.16%, amid supportive biotech-sector strength.
- The biotech sector is up 2.20%, amid positive clinical news from Krystal Biotech and FDA news from Legend Biotech.
- No fresh company-specific catalyst directly explaining the move was identified; Tscan’s Cellares manufacturing evaluation was announced earlier, on June 3, 2026.
- Broader indices are mixed, making the sector trend the clearer context for the gain.